WASHINGTON, May 2, 2023
/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA)
today announced its action against the federal government for the
uncompensated taking and misuse of Vanda's trade secrets and
confidential information. Vanda alleges that the U.S. Food and Drug
Administration (FDA) improperly provided confidential details from
Vanda's drug master files for its products, HETLIOZ® and
Fanapt®, to generic drug manufacturers during the FDA's
review of the manufacturers' Abbreviated New Drug Applications. The
action was filed in the United
States Court of Federal Claims and seeks an award of
economic damages. A copy of the complaint can be found
here (Vanda Pharmaceuticals Inc. v. USA, case no. 1:23-cv-00629-AOB).
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on
the development and commercialization of innovative therapies to
address high unmet medical needs and improve the lives of patients.
For more on Vanda Pharmaceuticals Inc., please visit
www.vandapharma.com and follow us on Twitter @vandapharma.
Corporate Contact:
Kevin
Moran
Senior Vice President, Chief Financial Officer and
Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Elizabeth Van Every
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
View original
content:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-sues-federal-government-for-misappropriation-of-trade-secrets-and-confidential-information-301813525.html
SOURCE Vanda Pharmaceuticals Inc.